Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 2
1968 1
1981 1
1988 1
1989 1
1992 2
1993 2
1994 4
1995 4
1996 3
1997 10
1998 5
1999 8
2000 9
2001 11
2002 7
2003 5
2004 8
2005 5
2006 12
2007 11
2008 9
2009 9
2010 6
2011 6
2012 9
2013 9
2014 11
2015 13
2016 15
2017 11
2018 11
2019 14
2020 21
2021 21
2022 19
2023 22
2024 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

308 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Understanding Cervical Cancer through Proteomics.
Martínez-Rodríguez F, Limones-González JE, Mendoza-Almanza B, Esparza-Ibarra EL, Gallegos-Flores PI, Ayala-Luján JL, Godina-González S, Salinas E, Mendoza-Almanza G. Martínez-Rodríguez F, et al. Among authors: salinas e. Cells. 2021 Jul 22;10(8):1854. doi: 10.3390/cells10081854. Cells. 2021. PMID: 34440623 Free PMC article. Review.
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators. Vergote I, et al. N Engl J Med. 2024 Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811. N Engl J Med. 2024. PMID: 38959480 Clinical Trial.
Memorable first impressions.
Salinas E, Sheikh BI. Salinas E, et al. Elife. 2024 May 3;13:e98274. doi: 10.7554/eLife.98274. Elife. 2024. PMID: 38700912 Free PMC article.
Eosinophils and Respiratory Viruses.
Flores-Torres AS, Salinas-Carmona MC, Salinas E, Rosas-Taraco AG. Flores-Torres AS, et al. Among authors: salinas e. Viral Immunol. 2019 Jun;32(5):198-207. doi: 10.1089/vim.2018.0150. Epub 2019 May 29. Viral Immunol. 2019. PMID: 31140942 Review.
Reply by Authors.
Deniffel D, Salinas E, Ientilucci M, Evans AJ, Fleshner N, Ghai S, Hamilton R, Roberts A, Toi A, van der Kwast T, Zlotta A, Finelli A, Haider MA, Perlis N. Deniffel D, et al. Among authors: salinas e. J Urol. 2020 Nov;204(5):1066-1067. doi: 10.1097/JU.0000000000001296. Epub 2020 Jul 23. J Urol. 2020. PMID: 32698718 No abstract available.
A randomized open-labeled study to examine the effects of creatine monohydrate and combined training on jump and scoring performance in young basketball players.
Vargas-Molina S, García-Sillero M, Kreider RB, Salinas E, Petro JL, Benítez-Porres J, Bonilla DA. Vargas-Molina S, et al. Among authors: salinas e. J Int Soc Sports Nutr. 2022 Aug 8;19(1):529-542. doi: 10.1080/15502783.2022.2108683. eCollection 2022. J Int Soc Sports Nutr. 2022. PMID: 35966022 Free PMC article. Clinical Trial.
Physiopathology of food allergies.
Reyes-Pavón D, Jiménez M, Salinas E. Reyes-Pavón D, et al. Among authors: salinas e. Rev Alerg Mex. 2020 Jan-Mar;67(1):34-53. doi: 10.29262/ram.v67i1.731. Rev Alerg Mex. 2020. PMID: 32447866 Review. English.
Urgent Commitment Issues.
Salinas E. Salinas E. Neuron. 2017 Aug 30;95(5):991-993. doi: 10.1016/j.neuron.2017.08.031. Neuron. 2017. PMID: 28858627 Free article.
308 results